Researchers from Vanderbilt University in Nashville, Tenn., focused on the loop-like structures of antibodies that link to HIV. The structures consist of 28 amino acids linked together in different combinations. Using computer programs, researchers were able to pinpoint which amino acid combination latched mostly tightly to HIV. They then optimized sequences to simulate vaccination events and fused these sequences to an antibody called PG9, which is known to neutralize HIV. These redesigned antibodies were able to disable HIV in laboratory testing.
The natural production of HIV neutralizing antibodies within the body typically take a year to occur and only happen in one-third of people. The researcher’s findings suggest a structure-based vaccine for HIV may be possible.
More articles on infection control:
First-ever dengue fever vaccine rolled out in Phillipines
Research reveals C. diff is more common in community than previously realized
141 medical organizations call on Congress to fund CDC research on gun violence
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
